TESARO (NASDAQ:TSRO) had its price target lowered by analysts at Morgan Stanley from $165.00 to $156.00 in a note issued to investors on Tuesday. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective points to a potential upside of 140.96% from the company’s previous close.

Several other brokerages have also recently commented on TSRO. Robert W. Baird reaffirmed a “neutral” rating and set a $125.00 target price on shares of TESARO in a report on Monday, October 2nd. Zacks Investment Research cut shares of TESARO from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. ValuEngine cut shares of TESARO from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. HC Wainwright initiated coverage on shares of TESARO in a research note on Thursday, October 12th. They issued a “buy” rating and a $158.00 price objective on the stock. Finally, Piper Jaffray Companies reissued a “neutral” rating and issued a $117.00 price objective on shares of TESARO in a research note on Monday, October 23rd. Three analysts have rated the stock with a sell rating, nine have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $152.26.

Shares of TESARO (NASDAQ:TSRO) traded down $4.85 on Tuesday, hitting $64.74. 834,543 shares of the stock traded hands, compared to its average volume of 1,093,056. TESARO has a 12 month low of $69.38 and a 12 month high of $192.94. The company has a market capitalization of $3,780.00, a PE ratio of -7.68 and a beta of 1.51. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.

TESARO (NASDAQ:TSRO) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The company had revenue of $142.77 million for the quarter, compared to analysts’ expectations of $130.57 million. During the same period last year, the firm earned ($1.72) earnings per share. The business’s revenue for the quarter was up 740.3% on a year-over-year basis. sell-side analysts forecast that TESARO will post -8.19 EPS for the current year.

In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the sale, the senior vice president now owns 8,101 shares of the company’s stock, valued at $690,529.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 34.60% of the company’s stock.

Several large investors have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of TESARO by 5.7% during the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after purchasing an additional 195,590 shares during the period. Vanguard Group Inc. lifted its holdings in shares of TESARO by 2.1% during the second quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock worth $416,537,000 after purchasing an additional 62,104 shares during the period. State Street Corp lifted its holdings in shares of TESARO by 17.9% during the second quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock worth $163,496,000 after purchasing an additional 177,057 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of TESARO by 24.9% during the third quarter. Janus Henderson Group PLC now owns 895,556 shares of the biopharmaceutical company’s stock worth $115,616,000 after purchasing an additional 178,406 shares during the period. Finally, BB Biotech AG lifted its holdings in shares of TESARO by 6.5% during the second quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after purchasing an additional 53,408 shares during the period.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/16/tesaro-tsro-price-target-cut-to-156-00-by-analysts-at-morgan-stanley.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related stocks with our FREE daily email newsletter.